INB03 for the Treatment of Pulmonary Complications From COVID-19
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of INB03 in the Treatment of Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)
Sponsor: Inmune Bio, Inc.
Terminated
Futility
Other terminated trials from Inmune Bio, Inc.
More terminations from Inmune Bio, Inc.
A PHASE2/PHASE3 clinical study on COVID-19, this trial is terminated or withdrawn. The trial is conducted by Inmune Bio, Inc. and has accumulated 8 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
Status: Recruiting → Terminated
-
Mar 2021 — Apr 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 3 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE2_PHASE3
Phase: PHASE2 → PHASE2_PHASE3
-
May 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Inmune Bio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .